Back to Search
Start Over
Rosiglitazone Treatment Prevents Postoperative Fibrosis in a Rabbit Model of Glaucoma Filtration Surgery
- Source :
- Investigative ophthalmologyvisual science. 60(7)
- Publication Year :
- 2019
-
Abstract
- Purpose To evaluate the potential antifibrotic effect of rosiglitazone (RSG), a peroxisome proliferator-activated receptor γ (PPARγ)-selective agonist, on subconjunctival fibrosis in a rabbit model of glaucoma filtration surgery (GFS) in vivo, and to investigate the underlying mechanisms in human Tenon's fibroblasts (HTFs) in vitro. Methods GFS were performed on adult male New Zealand white rabbits with chronic ocular hypertension previously established by injections of 2% methylcellulose into the anterior chamber. Rabbits were treated by RSG, mitomycin C (MMC) or 5-fluorouracil (5-FU) intraoperatively. The morphology of filtering blebs was evaluated by Indiana Bleb Appearance Grading Scale (IBAGS) scoring. Expression of profibrotic genes was determined by quantitative PCR, immunoblot, and/or histochemical analysis. In vitro studies were performed in a transforming growth factor (TGF)-β1-based cell model of fibrosis. Autophagy was evaluated by the formation of autophagosomes and autolysosomes using fluorescent and transmission electron microscopy and by expression of key mediators in the autophagic pathway. Results RSG treatment ameliorated a rebound intraocular pressure (IOP) elevation, prolonged the survival of filtering blebs, and attenuated subconjunctival fibrosis in rabbits following trabeculectomy. Pretreatment of HTFs with RSG inhibited TGF-β1-induced expression of profibrotic genes encoding specificity protein 1, connective tissue growth factor, and α smooth muscle actin. RSG augmented TGF-β1-induced autophagy in HTFs via a beclin1/VPS34-dependent mechanism. Augmentation of autophagy is associated with inhibition of TGF-β1-induced profibrotic gene expression by RSG. Conclusions RSG treatment prevents subconjunctival fibrosis after GFS by inhibition of profibrotic gene expression through a mechanism involved in promoting autophagy in local fibroblasts. RSG represents a novel antifibrotic drug with the potential to improve the success rate of GFS.
- Subjects :
- 0301 basic medicine
Male
Tenon Capsule
medicine.medical_treatment
Blotting, Western
Trabeculectomy
Pharmacology
Real-Time Polymerase Chain Reaction
Polymerase Chain Reaction
Rosiglitazone
Transforming Growth Factor beta1
03 medical and health sciences
0302 clinical medicine
Postoperative Complications
Microscopy, Electron, Transmission
Fibrosis
In vivo
medicine
Autophagy
Animals
Hypoglycemic Agents
Bleb (cell biology)
Intraocular Pressure
business.industry
Growth factor
Mitomycin C
Connective Tissue Growth Factor
Glaucoma
Fibroblasts
medicine.disease
Actins
Disease Models, Animal
030104 developmental biology
Microscopy, Fluorescence
030221 ophthalmology & optometry
Rabbits
business
Conjunctiva
Transforming growth factor
medicine.drug
Subjects
Details
- ISSN :
- 15525783
- Volume :
- 60
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Investigative ophthalmologyvisual science
- Accession number :
- edsair.doi.dedup.....74c0efbd28df331581cdcd1a4abf2a8e